Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated CIK and anti-CD3-MUC1 bispecific antibody in advanced lung cancer
NCT03501056Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of activated CIK cells + anti-CD3-MUC1 bispecific antibody in lung cancer, sponsored by Fuda Cancer Hospital. Planned start Mar 2018; status: withdrawn.
02
Drugs
activated CIK cells + anti-CD3-MUC1 bispecific antibody
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03501056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501056.